Company profile
Plus Therapeutics, Inc.
NASDAQ: PSTV · Healthcare · Biotechnology
#700 of 1,418 Healthcare companies by revenue32nd-percentile growth
EA Score
38DFH 26DQ 51GM 38SS 57
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$5.2M
Rev growth YoY (TTM)
-0.5%
Net income (FY)
-$22.4M
Employees
28
as of 2026-08-22
Market cap
$9.4M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.2M$5.2M2025
Net income-$22.4M-$22.4M2025
Operating income-$15.3M-$15.3M2025
Total assets$16.3M$16.3M2025
Liabilities$12.3M$12.3M2025
Equity$4.0M$4.0M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY17
FY17
FY18
FY18
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Grant100%
By geography
Not disclosed.
The read
What is Plus Therapeutics, Inc.’s revenue?
Plus Therapeutics, Inc. booked $5.2M in FY2025 revenue, contracting 10% year over year — slower than 68% of Healthcare companies we track, at a -429.4% net margin.
Peers · Healthcare
Biomerica, Inc.——Targeted Medical Pharma, Inc.——Plus Therapeutics, Inc.30DZeo ScientifiX, Inc.43DRadiko Holdings Corp——Petros Pharmaceuticals, Inc.47DNeighbors
Travis →Key facts
CEOMarc H. Hedrick
SectorHealthcare
IndustryBiotechnology
HeadquartersAustin, TX
ExchangeNASDAQ: PSTV
Employees28
IPO date2001-07-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.